Cargando…

Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis

BACKGROUND: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for hematologic malignancies and is predicted to experience widespread use in the near future. However, not all risks associated with this novel approach are well defined. There are few data in the r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ping, Zhou, Lili, Ye, Shiguang, Zhang, Wenjun, Wang, Junbang, Tang, Xiaochen, Liu, Jie, Xu, Yangyang, Qian, Wenbin, Liang, Aibin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8320511/ https://www.ncbi.nlm.nih.gov/pubmed/34335561 http://dx.doi.org/10.3389/fimmu.2021.638678

Ejemplares similares

Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy
por: Ni, Ying, et al.
Publicado: (2022)

Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation
por: Pawłowska, Małgorzata, et al.
Publicado: (2019)

Effects of antiviral therapy on post-hepatectomy HBV reactivation and liver function in HBV DNA-negative patients with HBV-related hepatocellular carcinoma
por: Gong, Wen-Feng, et al.
Publicado: (2017)

Glucocorticoids and Antivirals for HBV Reactivation in Onco-Hematologic Patients.
por: Marzano, Alfredo, et al.
Publicado: (2010)

Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative
por: Wang, Kai, et al.
Publicado: (2018)

The Role of Antiviral Prophylaxis in Preventing HBV and HDV Recurrence in the Setting of Liver Transplantation
por: Battistella, Sara, et al.
Publicado: (2023)

Discontinuation of antiviral prophylaxis correlates with high prevalence of hepatitis B virus (HBV) reactivation in rheumatoid arthritis patients with HBV carrier state: a real-world clinical practice
por: Mo, Ying-Qian, et al.
Publicado: (2014)

Resolved HBV behavior during the treatment of chronic HCV infection with direct-acting antivirals
por: Mohamed, Salem Y., et al.
Publicado: (2019)

High pretransplant HBV level predicts HBV reactivation after kidney transplantation in HBV infected recipients
por: Kim, Jong Man, et al.
Publicado: (2014)

Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis
por: Villeret, François, et al.
Publicado: (2023)

The Predictive Role of Hepatitis B Biomarkers on HBV Reactivation following Direct-Acting Antiviral Therapy in HBV/HCV Coinfected Patients
por: Tseng, Chih-Wei, et al.
Publicado: (2022)

HBV reactivation in an occult HBV infection patient treated with prednisone for nephrotic syndrome: case report and literature review
por: Du, Wenjun, et al.
Publicado: (2013)

Rituximab Administration and Reactivation of HBV
por: Tsutsumi, Yutaka, et al.
Publicado: (2010)

Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study
por: Mücke, Marcus M, et al.
Publicado: (2018)

Characterization of HBV surface antigen isoforms in the natural history and treatment of HBV infection
por: Rodgers, Mary A., et al.
Publicado: (2023)

Cost-effectiveness of managing HBV reactivation in patients with resolved HBV infection treated with anti-CD20 antibody for B-cell non-Hodgkin lymphoma
por: Fujita, Misuzu, et al.
Publicado: (2022)

Antiviral therapy inhibited HBV-reactivation and improved long-term outcomes in patients who underwent radiofrequency ablation for HBV-related hepatocellular carcinoma
por: Liu, Jian, et al.
Publicado: (2023)

Antiviral therapy of chronic HBV infection in pregnancy
por: Nikolajuk-Stasiuk, Julita, et al.
Publicado: (2016)

New biomarkers of hepatitis B virus (HBV) infection: HBV RNA and HBV core-related antigen, new kids on the block?
por: Lim, Young-Suk
Publicado: (2023)

Recent Advances in HBV Reactivation Research
por: Guo, Lixia, et al.
Publicado: (2018)

Risk Stratification for Hepatitis B Virus Reactivation in Kidney Transplant Recipients With Resolved HBV Infection
por: Tsai, Hsin-Ju, et al.
Publicado: (2023)

Incidence, risk factors, and clinical outcomes of HBV reactivation in non-liver solid organ transplant recipients with resolved HBV infection: A systematic review and meta-analysis
por: Yin, Saifu, et al.
Publicado: (2023)

In situ analysis of hepatitis B virus (HBV) antigen and DNA in HBV-induced hepatocellular carcinoma
por: Zheng, Ye, et al.
Publicado: (2022)

Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice
por: Ye, Lei, et al.
Publicado: (2017)

Antiviral Treatments Eliminate the Adverse Impacts of High Baseline HBV Loads on the Survival of HBV-Related HCC Patients
por: Hu, Zili, et al.
Publicado: (2022)

1248. Relationship Between ALT and New HBV Biomarkers in HBV/HIV Coinfected Persons Started on Antiviral Therapy
por: Rouster, Susan D, et al.
Publicado: (2022)

The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma
por: Yu, Liang-He, et al.
Publicado: (2011)

Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection
por: Kotake, Takeshi, et al.
Publicado: (2018)

Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins
por: Debelec-Butuner, Bilge, et al.
Publicado: (2022)

Risk of Hepatitis B Virus (HBV) Reactivation in Patients with Immune-Mediated Inflammatory Diseases Receiving Biologics: Focus on the Timing of Biologics after Anti-HBV Treatment
por: Ahn, Soo Min, et al.
Publicado: (2022)

Risk of Hepatitis B Virus (HBV) Reactivation in HBsAg-Negative, Anti-HBc-Negative Patients Receiving Rituximab for Autoimmune Diseases in HBV Endemic Areas
por: Lan, Ting-Yuan, et al.
Publicado: (2023)

ATM and ATR Expression Potentiates HBV Replication and Contributes to Reactivation of HBV Infection upon DNA Damage
por: Kostyusheva, Anastasiya, et al.
Publicado: (2019)

Application and Impact of Antiviral Therapy for Patients with HBV-Related Hepatocellular Carcinoma Receiving Sorafenib and Lenvatinib Treatment
por: Lee, I-Cheng, et al.
Publicado: (2022)

A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro
por: Salpini, Romina, et al.
Publicado: (2020)

The Hepatitis B Surface Antigen Binding Protein: An Immunoglobulin G Constant Region-Like Protein That Interacts With HBV Envelop Proteins and Mediates HBV Entry
por: Sun, Yeping, et al.
Publicado: (2018)

Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections(†)
por: De Clercq, Erik, et al.
Publicado: (2010)

Editorial: Interferon and its antiviral effect in response to HBV infection
por: Song, Hongxiao, et al.
Publicado: (2023)

Extrahepatic Manifestations of Chronic HBV Infection and the Role of Antiviral Therapy
por: Mazzaro, Cesare, et al.
Publicado: (2022)

S gene mutations of HBV in children with HBV-associated glomerulonephritis
por: Lu, Hongzhu, et al.
Publicado: (2012)

Author Correction: Enhanced antiviral and antifibrotic effects of short hairpin RNAs targeting HBV and TGF-β in HBV-persistent mice
por: Ye, Lei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rn171ihtgohc27mkmv23pldcf5